Developer of cellular drug discovery tools designed to provide medicines for cancer treatment.
Developer of cellular drug discovery tools designed to provide medicines for cancer treatment.
Drug Discovery📍 South San Francisco, CAFounded 2018
Current Valuation
$1.9B
as of 2024-Q3
UNICORN
QL Price
$1.6B
-11% vs last round
QuantLogix's current estimate for ArsenalBio, published 2026-09-27 — below the last disclosed round of $1.9B (2024-Q3).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$1.9B
2024-Q3
weight 0.25
Secondary market print
$1.6B
2026-06-27
weight 0.58
How this price has held up
No round has priced for ArsenalBio since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, ArsenalBio, 2026-09-27 (8e60d330f4ccee23).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is ArsenalBio going public?
No. ArsenalBio is private and has not filed to go public. There is no S-1 on file.
What is ArsenalBio's valuation in 2026?
ArsenalBio is valued at $1.9B as of 2024-Q3, set by its Series C ($325M, Sep 2024). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has ArsenalBio filed an S-1?
No public S-1 is on file for ArsenalBio.
How much has ArsenalBio raised?
ArsenalBio has raised $630.81M in total, most recently a Series C of $325M in Sep 2024.
Is ArsenalBio publicly traded — can you buy ArsenalBio stock?
No. ArsenalBio is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for ArsenalBio on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2018
HQ
South San Francisco, CA
Employees
216
Total Raised
$630.81M
Last Round
Series C — $325M (Sep 2024)
IPO Status
private
Fundraising Status
Series C · $325M · 2y ago
privateTotal raised $630.81M
Secondary Market
Implied price / share
$15.59
Last round price / share
$18.58
vs last round
-16.1%
Open interest
1
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series C
$325M
Sep 2024
—
$1.9B
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for ArsenalBio — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-27. Re-checked weekly.
Talent Signal
Hiring trend
▼ Hiring downtrend
-50% vs 2026-08
Open roles
1
via lever
Product-build share
0%
engineering, research, product, design
Trajectory
tightening
go-to-market push — Only 0% of open roles build product — hiring is concentrated in sales/marketing/ops (1 of 1 open roles are other).
Open roles trending down; no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Don't See Your Role Below?
Counted from ArsenalBio's live job board as of 2026-09-15; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2024-Q3. Refreshed quarterly.